Your browser doesn't support javascript.
loading
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
Mease, Philip J; Kellner, Herbert; Morita, Akimichi; Kivitz, Alan J; Aslanyan, Stella; Padula, Steven J; Topp, Andrew S; Eldred, Ann; Behrens, Frank; Papp, Kim A.
Afiliação
  • Mease PJ; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. pmease@philipmease.com.
  • Kellner H; Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA, 98122, USA. pmease@philipmease.com.
  • Morita A; Hospital Neuwittelsbach, Munich, Germany.
  • Kivitz AJ; Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Aslanyan S; Altoona Center for Clinical Research, Duncansville, PA, USA.
  • Padula SJ; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Topp AS; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Eldred A; AbbVie Inc., North Chicago, IL, USA.
  • Behrens F; AbbVie Inc., North Chicago, IL, USA.
  • Papp KA; CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany.
Rheumatol Ther ; 9(5): 1361-1375, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35931879
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article